AVIR News and Press, Atea Pharmaceuticals Inc. From 08/01/23

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patien...

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, P...

2023-05-30 09:11:45 ET Atea Pharmaceuticals ( NASDAQ: AVIR ), a company focused on oral antivirals, added ~3% pre-market Tuesday after announcing that its board of directors unanimously rejected an unsolicited takeover offer from Tang Capital Partners, LP. Following a revi...

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that its Board of Directors una...

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cas...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 34.73% on the day to $4.99. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, ...

2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...

2023-05-22 09:27:08 ET Atea Pharmaceuticals ( NASDAQ: AVIR ) soared 24% in premarket trading after Tang Capital affiliate Concentra Biosciences offered to buy Atea for $5.75 a share in cash. The offer also includes a contingent value right  representing the right to r...

2023-05-08 20:51:06 ET Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Results Conference Call May 08, 2023 04:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief E...